Tag: risk stratification

The PRISM (Pediatric Risk of Mortality) score is a validated severity-of-illness scoring system designed for pediatric patients (newborn to 18 years) in pediatric intensive care units (PICUs). Developed in 1988 and refined in subsequent iterations (PRISM III and PRISM IV), it quantifies disease severity and predicts hospital mortality risk based on physiological and laboratory data collected within the first 24 hours of PICU admission. PRISM is widely used to assess critically ill children, excluding premature neonates in neonatal ICUs (NICUs), where scores like CRIB II or SNAP-II are preferred.

The APACHE II (Acute Physiology and Chronic Health Evaluation II) score is a widely used severity-of-illness scoring system designed for adult patients in intensive care units (ICUs). Developed in 1985, it quantifies disease severity and predicts hospital mortality risk based on physiological measurements, age, and chronic health status. The score is calculated within the first 24 hours of ICU admission and is applicable across a broad range of adult critical care conditions. It is a cornerstone tool for risk stratification, quality assessment, and research in ICUs.

The CRIB II (Clinical Risk Index for Babies II) score is a validated risk-adjustment tool designed for use in neonatal intensive care units (NICUs) to predict mortality risk in preterm or very low birth weight (VLBW) newborns, specifically those born at <32 weeks gestation or weighing ≤1500 grams. It provides a standardized, objective method to assess illness severity and mortality risk within the first hour of NICU admission, aiding clinicians in risk stratification, quality assessment, and research.

The prostate gland, an integral component of the male reproductive system, can develop malignant tumors that significantly impact urological health. This comprehensive guide examines prostate cancer's anatomical presentation, diagnostic approaches, and current treatment modalities, providing essential information for medical professionals and students in understanding this prevalent male cancer.